Nanovibronix, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Christian Michael Glibert is no longer a 10% beneficial owner of ENvue Medical, Inc. due to share dilution from a merger.
ENvue Medical, Inc. Director and 10% owner Christian Michael Glibert acquired 240,000 shares of common stock.
Bank of America and its subsidiaries reported significant sales of ENvue Medical, Inc. common stock, reducing their indirect beneficial ownership to 8 shares.
NanoVibronix CEO, Brian M. Murphy, acquired 80,000 stock options at an exercise price of $0.5995 on December 30, 2024.
Director Thomas Mika acquired 20,000 options to purchase common stock of NanoVibronix, Inc. on December 30, 2024.
NanoVibronix's Chief Financial Officer, Stephen Russell Brown, acquired 50,000 options to purchase common stock at $0.5995 per share on December 30, 2024.
Maria Schroeder, a director at NanoVibronix, Inc., acquired 20,000 options to purchase common stock on December 30, 2024.
A director of NanoVibronix, Inc. acquired 23,000 options to purchase common stock at $0.5995 per share on December 30, 2024.
Director Michael Ferguson of NanoVibronix, Inc. acquired 20,000 options to purchase common stock at $0.5995 per share on December 30, 2024.
Harold Jacob, Chief Medical Officer of NanoVibronix, Inc., acquired 10,000 stock options at an exercise price of $0.5995 on December 30, 2024.
Christopher M. Fashek, a director at NanoVibronix, Inc., acquired 50,000 options to purchase common stock on December 30, 2024.
Director Aurora Cassirer acquired 20,000 options to purchase common stock of NanoVibronix, Inc. on December 30, 2024.